Clinical Trials Logo

Liver Transplantation clinical trials

View clinical trials related to Liver Transplantation.

Filter by:

NCT ID: NCT05818644 Enrolling by invitation - Pediatric ALL Clinical Trials

Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children

HEPATIC
Start date: September 28, 2023
Phase:
Study type: Observational

The goal of this observational study is to investigate the incidence, current management practices, and outcomes in pediatric patients with HAC after liver transplantation. Research question: - What are the overall incidence of HAC and the effectiveness of all treatment strategies for HAC after pediatric LT? - What are the current management practices in the experience of centers, anticoagulant therapy, screening protocol, and assessment criteria for HAC after pediatric LT? The burden of participation is considered to be minimal, and limited to the questionnaires.

NCT ID: NCT05807802 Not yet recruiting - Clinical trials for Liver Transplant; Complications

FSTL1 and PPCs on Pediatric Within LDLT:a Prospective Cohort Analysis

Start date: May 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to identify the association between FSTL1 elevation and acute lung injury (ALI) after pediatric liver transplantation.The main questions it aims to answer what the risk factors are for ALI in children and to evaluate the predictive value for the development of ALI.Participants will be divided into non-ALI group and ALI group according to whether they had ALI in a week after liver transplantation.Researchers will compare the difference between the two groups and use multivariate logistic regression analysis to screen the risk factors of ALI, and receiver operating characteristic(ROC) curve was used to evaluate the predictive efficacy of risk factors.

NCT ID: NCT05763446 Recruiting - Clinical trials for Liver Transplant; Complications

Predictive Factors for Massive Transfusion During Liver Transplantation

TRADIFEG
Start date: July 31, 2021
Phase:
Study type: Observational

Liver transplantation (LT) is the treatment of choice for patients with end-stage liver disease (1). LT is often associated with severe intraoperative blood loss and the literature has had a great interest in clarifying the predictive factors for transfusion requirements during this surgery. Despite the advances in surgical techniques, graft preservation, and anesthetic management achieved over the past two decades, intraoperative bleeding and blood component consumption during LT are still issues of current interest. The requirement for blood components is highly variable between different transplant centers and ranges from none to many units of red blood cells (RBC), plasma, and platelets per patient. Bleeding associated with LT is multifactorial. Among the pre-transplantation factors, portal hypertension and coagulation defects are of great importance. The latter can develop or amplify during the anaepatic and/or neohepatic phase due to the absence of hepatic metabolic function, hyperfibrinolysis or platelet sequestration in the graft. In the literature, the higher transfusion requirement (HTR) is associated with worse postoperative outcomes, with an increase in both the length of stay in the intensive care unit (ICU) and in hospital, and mortality.

NCT ID: NCT05761483 Recruiting - Biliary Stricture Clinical Trials

Endoscopic Management of Non-anastomotic Biliary Strictures Following Liver Transplantation.

STEBINANSIED
Start date: March 12, 2020
Phase:
Study type: Observational [Patient Registry]

The study will evaluate the results of endoscopic treatment of NON-anastomotic biliary strictures following liver transplantation

NCT ID: NCT05760235 Recruiting - Obesity Clinical Trials

Prospective Pilot Study for the Evaluation of Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Liver Transplant Candidates

ESGiTX
Start date: October 13, 2022
Phase: N/A
Study type: Interventional

The goal of this pilot prospective interventional study is to evaluate the efficacy of endoscopic sleeve gastroplasty (ESG) in allowing obese subjects with the need of liver transplantation to reduce their BMI in order to enter the waiting list (BMI (≥35 kg/m2). The main question[s] it aims to answer are: - Is the procedure effective in reducing BMI to the target level in 12 months? - Which is the effect on weight loss, quality of life and obesity-related comorbidities? Participants will undergo ESG as per standard clinical practice and followed up to 12 months before transplantation and for 12 months after transplantation

NCT ID: NCT05754242 Recruiting - Clinical trials for Liver Transplantation

Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation

VITACTOH
Start date: November 17, 2020
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are: - Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ? - Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation? - Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ? Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft. Researchers will compared the incidence of postreperfusion syndrome in both groups.

NCT ID: NCT05752058 Not yet recruiting - Clinical trials for Liver Transplantation

Risk Factors for Early Acute Lung Injury After Liver Transplantation in Children

Start date: August 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to identify the risk factors for early acute lung injury (ALI) after liver transplantation in children .The main questions it aims to answer are what the risk factors are for early ALI in children and to evaluate the predictive value for the development of ALI.Participants will be divided into non-ALI group and ALI group according to whether they had ALI in a week after liver transplantation.Researchers will compare the difference between the two groups and use multivariate logistic regression analysis to screen the risk factors of ALI, and receiver operating characteristic(ROC) curve was used to evaluate the predictive efficacy of risk factors.

NCT ID: NCT05750329 Not yet recruiting - Clinical trials for Liver Transplant Disorder

Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)

Start date: August 2023
Phase: N/A
Study type: Interventional

Colon cancer and primary liver cancer are common malignant tumors with low survival rate worldwide, and unresectable primary liver cancer and colon cancer liver metastases have worse prognosis. End-stage liver disease is equated with advanced liver disease, liver failure and decompensated cirrhosis because they are generally irreversible. Liver transplantation is a treatment option for the above-mentioned patients and is expected to improve the prognosis of the patients, but the biggest problem faced by such patients is the shortage of donor livers. Recently, a new surgical modality, resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID), can greatly alleviate these problems.Based on clinical surgical experience, our center proposes and designs a clinical study of adjuvant liver transplantation combined with two-stage hepatectomy in the treatment of patients with unresectable primary liver cancer, colorectal cancer liver metastases, or end-stage liver disease. By improvement of RAPID operation, the safety and efficacy of this treatment method in patients with those disease were evaluated.

NCT ID: NCT05733754 Not yet recruiting - Clinical trials for Liver Transplant; Complications

Proteinuria in Liver Transplantation, a Single Egyptian Center Study

Start date: March 2023
Phase:
Study type: Observational

Proteinuria has been suggested to be a predictive factor and an important tool for differentiating the etiology of renal dysfunction in various clinical scenarios .The good predictive performance of preoperative proteinuria utilized for the development of renal failure after operation has been reported . In the literature, prognostic significance of several scoring systems for end-stage liver disease has been validated . The Sequential Organ Failure Assessment (SOFA) system was found to be superior to ChildPugh points (CP points) and Model for End-Stage Liver Disease (MELD) score, and postoperative day 7 SOFA had the best discriminative power for predicting 3-month and 1-year mortality after liver transplantation . Renal dysfunction is one of the most significant adverse events in patients awaiting or undergoing a liver transplant, and its occurrence generally indicates a high rate of poor prognosis

NCT ID: NCT05707520 Recruiting - Clinical trials for Liver Transplant Rejection

Long-term Benefit of MPA in Liver Transplantation

Start date: December 4, 2022
Phase:
Study type: Observational

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.